argenx SE announced it will acquire Forte Biosciences for approximately $2.2 billion in cash, paying $77 per share. This acquisition adds Forte's lead drug candidate FB102, a first-in-class anti-CD122 antibody with promising Phase 1b results in vitiligo and celiac disease, to argenx's immunology portfolio. The deal strengthens argenx's position in autoimmune disease treatment by expanding its pipeline with a novel approach targeting T-cell and NK-cell activity. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and customary conditions.
During week 30 of 2026 (July 20-24), Sampo Oyj bought back a total of 1,352,794 of its A-shares at a weighted average price of €9.60 per share. This share buyback is part of a program authorized by the company's general meeting on April 22, 2026, wit...
InterContinental Hotels Group PLC repurchased 1,000 of its ordinary shares on July 24, 2026, through Goldman Sachs International on the London Stock Exchange. The shares were bought at prices ranging from $153.20 to $156.00, with an average price of ...
On July 26, an attacker exploited owner privileges in WEMIX's stablecoin contract to mint about 5.23 million unauthorized WEMIX$ tokens, worth roughly $724,000 in converted assets. WEMIX responded by suspending bridges, liquidity pools, and related s...
Bitcoin exchange-traded funds (ETFs) attracted $33 million in net inflows last week, marking a reversal from earlier 2026 outflows. This renewed investor interest in Bitcoin through traditional markets suggests growing confidence in the asset. Market...
Charter Communications is currently valued below 1x adjusted EBITDA amid challenges like customer losses and fiber competition. However, growth in mobile subscribers and network upgrades support a positive long-term outlook. The company boasts a stro...
